Cosmos Health's Cana Secures 3-Year Deal to Manufacture 3.9M Progesterone Pessaries
COSM•Cosmos Health's Cana Laboratories secured a three-year contract to manufacture 3.9 million units of VASCLOR GEST 400mg progesterone vaginal pessaries, delivering 1.3 million units annually. The agreement expands Cana’s high-margin manufacturing division into women’s health and diversifies its customer base under European GMP certification.
1. Contract Manufacturing Agreement
Cosmos Health's subsidiary Cana Laboratories entered into a three-year agreement to produce 3.9 million units of VASCLOR GEST 400mg vaginal pessaries, supplying 1.3 million units annually in boxes of 15 pessaries.
2. Strategic Expansion
This deal marks Cana’s expansion into women’s health and reproductive medicine, diversifying its high-margin contract manufacturing order book and adding Verisfield S.A. as a new international customer.
3. Operational Capacity
Cana will leverage its European GMP-certified infrastructure, including upgraded facilities and production capacity, to fulfill the agreement and position itself for further contract awards.
4. Company Overview
Cosmos Health is a vertically integrated global healthcare group offering pharmaceuticals, nutraceuticals, and contract manufacturing through its Cana Laboratories subsidiary, with distribution across Europe, the UK, and North America.
